Current Headlines

  1. Trevena Announces Successful End-Of-Phase 2 Meeting With FDA And Outlines Phase 3 Program For Oliceridine
    5/2/2016

    Trevena, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, recently announced the successful completion of the End-of-Phase 2 Meeting process with the United States Food and Drug Administration (FDA)

  2. Oligomerix Awarded A Grant For Its Alzheimer’s Drug Discovery Program Targeting Tau Oligomers From The National Institutes Of Health
    5/2/2016

    Oligomerix, Inc., a privately held company targeting tau oligomers for developing disease modifying therapeutics for Alzheimer’s disease (AD) and related neurodegenerative disorders, announced recently the receipt of an award for a Direct-to-Phase-II Small Business Innovation Research (SBIR) grant for a two year program for a total of $1.5 M from the National Institutes of Health (NIH), National Institute on Aging (NIA)

  3. Grafix Demonstrates Superior Clinical Outcomes Compared With EpiFix In ‘Real World’ Study
    5/2/2016

    Osiris Therapeutics, Inc., a leading cellular and regenerative medicine company, focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announces the results of A Retrospective, Single-Center, Non-Randomized, Cross-Sectional Comparative Effectiveness Study Evaluating Surface Area Reduction, Volume Reduction and Closure Rates in Acute and Chronic Wounds Managed with Grafix versus EpiFix

  4. Nexvet And Zenoaq Announce PD-1 mAb Candidate For Canine Cancer
    5/2/2016

    Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, and Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.), a leading Japanese animal health company, announced today their research and development collaboration has yielded fully caninized, or ‘100% dog’, monoclonal antibodies (mAbs) that bind and potently inhibit the immuno-oncology target programmed cell death protein 1 (PD-1).

  5. BIO Collaborates With NIH And NSF On Growing ‘Innovation Zone’ At BIO 2016 International Convention
    4/29/2016

    The Biotechnology Innovation Organization (BIO), the National Science Foundation (NSF) and the National Institutes of Health (NIH) recently announced an agreement to feature Small Business Innovation Research (SBIR)-funded early-stage biomedical companies in an expanded Innovation Zone at the 2016 BIO International Convention

  6. Certara Launches New E-learning Platform For Biosimulation Education
    4/28/2016

    Certara®, the global biosimulation technology-enabled drug development company, recently launched an e-learning platform through Certara University to satisfy the increased need for education in the burgeoning field of biosimulation or model-based drug development

  7. twoXAR Joins Stanford University In Hunt For Medicines Targeting Rare Diseases
    4/28/2016

    twoXAR, Inc., a company dedicated to improving health through computation, recently announced a collaboration with Joyce Teng, MD, PhD, of the Department of Dermatology at Stanford University to support research focused on the identification of drug candidates targeting rare disorders such as lymphatic malformation and epidermolysis bullosa simplex (EBS)

  8. Partners HealthCare Announces The 2016 ‘Disruptive Dozen’ Technologies That Can Revolutionize Cancer Care
    4/27/2016

    Partners HealthCare recently announced its selections for the second annual “Disruptive Dozen,” the 12 emerging technologies with the potential to revolutionize cancer care over the next decade

  9. X-Chem Announces Achievement Of Milestone In Alexion Collaboration
    4/27/2016

    X-Chem, Inc. (X-Chem), a privately held biotechnology company utilizing its industry-leading DNA-Encoded X-Chem (DEX) drug discovery platform for the identification of first-in-class small molecule therapeutics, recently announced that it has achieved a milestone in its drug discovery collaboration with Alexion Pharmaceuticals, Inc., triggering a payment to X-Chem

  10. Evotec And Ex Scientia Announce Partnership To Discover Bispecific Small Molecule Immuno-Oncology Therapeutics
    4/26/2016

    Evotec AG and ex scientia Ltd (Dundee, UK) recently announced a collaboration with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies